IRF5 is an autoimmune-associated transcription factor genetically linked to inflammatory bowel disease (IBD) and other autoimmune disorders. At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5 degrader, in models of IBD.
Kymera’s IRF5 degrader shows potential in IBD treatment
